EBioMedicine

Scope & Guideline

Transforming research into accessible knowledge.

Introduction

Immerse yourself in the scholarly insights of EBioMedicine with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN2352-3964
PublisherELSEVIER
Support Open AccessYes
CountryNetherlands
TypeJournal
Convergefrom 2014 to 2024
AbbreviationEBIOMEDICINE / EBioMedicine
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS

Aims and Scopes

EBioMedicine aims to advance the field of biomedical research by publishing high-quality studies that contribute to our understanding of disease mechanisms, therapeutic strategies, and preventive measures. The journal emphasizes interdisciplinary research that integrates clinical and translational science, fostering collaboration among researchers, clinicians, and policy makers.
  1. Clinical and Translational Research:
    The journal focuses on studies that bridge the gap between laboratory research and clinical application, highlighting research that leads to the development of new diagnostic tools, treatment strategies, and preventive measures for diseases.
  2. Biomarker Discovery and Validation:
    A significant emphasis is placed on the identification and validation of biomarkers that could aid in disease diagnosis, prognosis, and treatment response, particularly in cancer, infectious diseases, and chronic conditions.
  3. Immunology and Infectious Diseases:
    Research on the immune response to infections, including the development of vaccines and therapeutic interventions, is a core area of focus, especially in the context of emerging infectious diseases like COVID-19.
  4. Genomics and Personalized Medicine:
    The journal publishes studies leveraging genomic data to tailor medical treatments to individual patient profiles, advancing the field of precision medicine across various diseases.
  5. Microbiome Research:
    The role of the microbiome in health and disease, including its impact on metabolic disorders, immune response, and treatment outcomes, is a growing area of interest in the journal.
  6. Novel Therapeutics and Drug Development:
    Studies investigating new therapeutic approaches, including drug repurposing, nanomedicine, and gene therapies, are highlighted, emphasizing innovative strategies to combat diseases.
Recent trends in EBioMedicine reflect a shift toward innovative and multidisciplinary research themes, aligning with current global health challenges and advancements in biomedical science.
  1. Artificial Intelligence and Machine Learning:
    The integration of AI and machine learning in research methodologies is increasingly prominent, with studies focusing on predictive modeling, diagnostic algorithms, and personalized treatment strategies.
  2. Long COVID and Post-Acute Sequelae:
    Research addressing the long-term effects of COVID-19, including post-acute sequelae, is rapidly expanding, reflecting the ongoing impact of the pandemic on public health.
  3. Metabolomics and Lipidomics:
    There is a growing focus on metabolomic and lipidomic profiling to understand disease mechanisms and identify biomarkers, particularly in metabolic disorders and cancer.
  4. Immunotherapy and Immune Profiling:
    Studies exploring immunotherapy, including novel approaches and immune profiling for various cancers, are gaining traction, driven by advances in understanding the immune system.
  5. Microbiome-Health Interactions:
    Research on the interactions between the microbiome and various health conditions, including metabolic and autoimmune diseases, is emerging as a significant area of interest.
  6. Genetic and Epigenetic Research:
    The exploration of genetic and epigenetic factors influencing disease susceptibility and treatment response is on the rise, particularly in chronic diseases and cancers.

Declining or Waning

While EBioMedicine has consistently published impactful research, certain themes are showing signs of declining prominence in recent publications. This shift may reflect changes in research focus or evolving scientific priorities.
  1. Traditional Pharmacology:
    Research focusing solely on traditional pharmacological approaches without considering personalized or genomic strategies is becoming less common, as the field moves towards more tailored therapeutic interventions.
  2. Single-Disease Focus:
    There is a noticeable decline in studies that concentrate exclusively on single diseases without considering the broader implications or comorbidities, as interdisciplinary approaches gain traction.
  3. Basic Science Without Clinical Relevance:
    Basic research studies that do not translate into clinical applications or relevance are being overshadowed by studies emphasizing translational impact, as the demand for clinically applicable findings increases.
  4. Static Models of Disease:
    Research using static models that do not account for dynamic biological processes or the complexity of disease interactions is less favored, with a shift towards more comprehensive and integrated modeling approaches.
  5. Conventional Imaging Techniques:
    There is a waning interest in conventional imaging techniques as advanced technologies, including AI-based methods and multimodal imaging, become more prevalent in research design.

Similar Journals

Annual Review of Pathology-Mechanisms of Disease

Transforming Knowledge into Pathological Solutions
Publisher: ANNUAL REVIEWSISSN: 1553-4006Frequency: 1 issue/year

Annual Review of Pathology: Mechanisms of Disease is a premier scholarly journal published by ANNUAL REVIEWS that systematically reviews significant advancements in the field of pathology and the mechanisms underpinning various diseases. With an ISSN of 1553-4006 and an E-ISSN of 1553-4014, the journal has established its importance within the academic community, evidenced by its prestigious Q1 rankings in several categories including medicine, pathology, forensic medicine, and plant science for 2023. Notably, it ranks #1 out of 208 in the pathology and forensic medicine category, placing it in the 99th percentile according to Scopus metrics. Although not an open-access journal, it offers crucial insights to researchers, professionals, and students alike by providing a comprehensive understanding of pathophysiological concepts and emerging trends. The journal continues to be an essential resource for those dedicated to advancing research and practical applications in disease mechanisms.

Med

Pioneering Interdisciplinary Insights in Medicine.
Publisher: CELL PRESSISSN: 2666-6340Frequency: 12 issues/year

Med, an esteemed journal published by CELL PRESS, stands at the forefront of interdisciplinary medical research, making significant contributions to the field of Medicine since its inception in 2020. With an impressive Q1 ranking in the Medicine (miscellaneous) category and a notable 96th percentile ranking in General Medicine according to Scopus, this journal is dedicated to disseminating high-quality research that advances medical knowledge and practice. Med provides a platform where researchers, professionals, and students can share their findings and insights, fostering a collaborative environment that bridges various aspects of medicine. While offering a comprehensive body of research, Med is committed to promoting open communication within the scientific community, ensuring that valuable information is accessible to those who seek to enhance their understanding and application of medical science. With a strong presence in the United States and a global readership, Med is poised to influence the future of healthcare significantly.

JCI Insight

Fostering Collaboration for Healthier Futures
Publisher: AMER SOC CLINICAL INVESTIGATION INCISSN: Frequency: 24 issues/year

JCI Insight, published by the American Society for Clinical Investigation, stands as a vital resource in the field of medicine, having achieved a prestigious Q1 rating in the 2023 category for miscellaneous medicine. With an impressive Scopus rank of 27 out of 636, placing it in the 95th percentile, this journal emphasizes the dissemination of high-quality, peer-reviewed research that pushes the boundaries of clinical and translational science. Since becoming an Open Access journal in 2020, JCI Insight has expanded its reach, providing researchers, professionals, and students around the globe with unfettered access to groundbreaking studies and reviews. The journal focuses on a wide spectrum of topics relevant to the medical community, making it an essential platform for sharing innovative findings and fostering collaboration among scientists dedicated to transforming health outcomes. Based in Ann Arbor, Michigan, JCI Insight continues to inspire advancements in medical research, contributing significantly to the ongoing dialogue in the ever-evolving healthcare landscape.

TRENDS IN IMMUNOLOGY

Navigating the Evolving Landscape of Immunology
Publisher: CELL PRESSISSN: 1471-4906Frequency: 12 issues/year

TRENDS IN IMMUNOLOGY, published by CELL PRESS, stands as a premier source of insights and developments within the field of immunology. With an ISSN of 1471-4906 and E-ISSN of 1471-4981, this journal has established a strong reputation, evidenced by its prestigious status in Q1 quartiles for both Immunology and Allergy in 2023. It is ranked #13 out of 233 in the Scopus category of Medicine – Immunology and Allergy, and #16 out of 236 in Immunology and Microbiology, placing it within the top 94th and 93rd percentiles respectively. Since its inception in 1987, TRENDS IN IMMUNOLOGY has provided a critical platform for researchers, professionals, and students to access the latest advancements and integrative reviews in immunological research. The journal offers open access options, enhancing the accessibility of its high-impact content to a global audience. Researchers and practitioners rely on its pages not only for cutting-edge findings but also for comprehensive discussions that drive the future of immunology research.

Biomedical Reports

Innovating research for a healthier tomorrow.
Publisher: SPANDIDOS PUBL LTDISSN: 2049-9434Frequency: 6 issues/year

Biomedical Reports, published by SPANDIDOS PUBL LTD in Greece, is a distinguished open-access journal that focuses on the dynamic fields of biochemistry, genetics, molecular biology, medicine, pharmacology, and neuroscience. Established in 2014, the journal has rapidly gained recognition, securing Q2 and Q3 rankings in several categories for 2023, including a notable ranking of #125/636 in General Medicine, placing it in the 80th percentile amongst its peers. The journal continually aims to disseminate innovative research findings that advance the understanding of complex biomedical issues, making it an invaluable resource for researchers, professionals, and students alike. Its multidisciplinary approach not only reflects the interconnectivity of modern biomedical sciences but also promotes collaborative discourse among diverse fields, ensuring ongoing relevance and impact within the scientific community.

BIOMARKERS

Charting New Territories in Biomarker Science
Publisher: TAYLOR & FRANCIS LTDISSN: 1354-750XFrequency: 8 issues/year

BIOMARKERS is a distinguished journal published by Taylor & Francis Ltd, focusing on the critical intersection of biochemistry, clinical biochemistry, and health-related toxicology. With a robust history of publication since 1996 and ongoing contributions through to 2024, the journal serves as a vital platform for researchers, professionals, and students keen on exploring innovative biomarker research that spans various domains within the life sciences. The journal is currently ranked in the Q3 quartile in key areas such as Biochemistry and Health, demonstrating its reputation in the scientific community. Although it operates under a subscription model, BIOMARKERS remains an essential resource for advancing knowledge on biomarkers in health and disease, reflecting the latest advancements and methodologies within the rapidly evolving landscape of biomedical research. Researchers looking to publish in this influential journal can expect a rigorous peer-review process aimed at ensuring the dissemination of high-quality scientific inquiry.

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Elevating Insights in Genetics and Molecular Medicine
Publisher: TAYLOR & FRANCIS ASISSN: 1473-7159Frequency: 12 issues/year

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, published by Taylor & Francis AS, serves as a pivotal platform for facilitating advanced research and discourse in the fields of Genetics, Molecular Biology, Molecular Medicine, and Pathology. With an impressive Impact Factor and a distinguished status as Q2 in multiple categories, along with a prestigious Q1 ranking in Pathology and Forensic Medicine (2023), this journal continues to attract contributions from leading experts and budding researchers alike. The journal aims to address critical developments in molecular diagnostics, providing insightful reviews that propel the understanding and application of diagnostic techniques in various medical contexts. Accessible to a diverse audience in the academic community, the journal emphasizes the importance of molecular diagnostics in both clinical and laboratory settings, promoting innovative methodologies and comprehensive evaluations of emerging technologies. With ongoing convergence of scientific discovery advancing rapidly from 2001 through 2024, EXPERT REVIEW OF MOLECULAR DIAGNOSTICS remains essential for those committed to furthering the fields of molecular diagnostics and healthcare advancements globally.

Journal of Biomedical Research

Elevating Biomedical Research Through Rigorous Scholarship
Publisher: NANJING MEDICAL UNIVISSN: 1674-8301Frequency: 6 issues/year

Journal of Biomedical Research, published by Nanjing Medical University in China, is a prominent platform for groundbreaking discoveries in the fields of Biochemistry, Genetics, and Molecular Biology, as well as Medicine. With an ISSN of 1674-8301 and an E-ISSN of 1876-4819, the journal offers a vital opportunity for researchers, professionals, and students to disseminate insightful research findings. Although not currently available as an open access journal, its inclusion in the second quartile of both Biochemistry and Medicine categories underscores its growing influence and commitment to high-quality scholarship, as evidenced by its historical compliance with Scopus rankings prior to 2009. By fostering an interdisciplinary approach, the Journal of Biomedical Research aims to bridge gaps in current biomedical understanding and encourages innovative research that can lead to significant contributions in improving health outcomes. Its editorial policies guarantee rigorous peer review, making it a trusted source of knowledge in the biomedical community.

CANCER GENE THERAPY

Exploring Breakthroughs in Cancer Gene Innovations
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

CYTOKINE

Connecting researchers to the forefront of biomedical innovation.
Publisher: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDISSN: 1043-4666Frequency: 12 issues/year

CYTOKINE is a prestigious peer-reviewed journal published by Academic Press Ltd - Elsevier Science Ltd, dedicated to advancing the field of immunology, biochemistry, and related biomedical sciences since its inception in 1989. With an ISSN of 1043-4666 and an E-ISSN of 1096-0023, this journal serves as a vital resource for researchers and professionals alike, offering cutting-edge research findings that delve into the roles and mechanisms of cytokines in health and disease. Recognized for its impactful contributions, CYTOKINE currently ranks in the Q2 quartile across several categories, including Biochemistry, Hematology, and Immunology, indicating its significant influence in these fields. Despite not offering open access, the journal maintains a high-quality standard, as evidenced by its robust Scopus rankings, including a notable 80th percentile in Medicine and Hematology. Researchers and students are encouraged to explore the latest findings and methodologies via CYTOKINE, as it continues to shape the future landscape of cytokine research and application.